Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1/2 1

Status

Terminated 2

Sponsor Class

OTHER 2INDUSTRY 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 9Sarcoma 2

Conditions

Sarcoma 317Gastrointestinal Stromal Tumors 108Neoplasms 105Breast Neoplasms 92Melanoma 81Ovarian Neoplasms 79Neoplasm Metastasis 74Carcinoma, Non-Small-Cell Lung 74Colorectal Neoplasms 70Osteosarcoma 61Stomach Neoplasms 59Pancreatic Neoplasms 55Bone Neoplasms 55Prostatic Neoplasms 51Head and Neck Neoplasms 48Glioblastoma 48Sarcoma, Ewing 47Lung Neoplasms 45Esophageal Neoplasms 42Squamous Cell Carcinoma of Head and Neck 41Carcinoma, Renal Cell 40Uterine Cervical Neoplasms 39Sarcoma, Kaposi 38Lymphoma 37Urinary Bladder Neoplasms 36Sarcoma, Synovial 36Recurrence 35Dendritic Cell Sarcoma, Interdigitating 34Lymphoma, Non-Hodgkin 33Endometrial Neoplasms 33

Interventions

Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Neurofibromatoses × Sarcoma × Clear all
NCT05011019 2024-03-21

A Clinical Trial to Evaluate the Safety and Efficacy of AL2846 Capsules in Chinese Patients With Type I Neurofibromatosis

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 1/2 Terminated
22 enrolled
CNSSarcoma

Neurofibromatoses, Neurofibrosarcoma

NCT00427583 2012-08-07

Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors

Novartis

Phase 2/3 Terminated
11 enrolled
CNSSarcoma

Neurofibromatoses, Nerve Sheath Neoplasms, Neurofibrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡